News

One study will be in previously untreated (naive) patients and the other in patients who failed prior treatment (relapsers and nonresponders), an area of great unmet medical need.

A Phase I open-label pilot study was conducted to evaluate the safety (primary endpoint) and preliminary efficacy of escalating single doses of MDX-1100 in 11 patients with moderate

The Reveal-1 trial is being conducted in previously untreated elderly patients with acute myeloid leukemia (AML) who are unlikely to benefit from standard induction therapy. Patients enrolled in

The agreement also gives Pfizer exclusive rights to the use of this vaccine targeting the tumor specific EGFR mutant EGFRvIII in other potential indications. On April 16, 2008,

Pentech will contribute its ANDA filing for a generic equivalent to Luxiq foam, a $34 million branded pharmaceutical product, to the agreement. Perrigo will contribute two of its

As the first company to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing

Michael Wells, CEO of Aton Pharma, said: “This partnership marks an important milestone for Aton as we execute our mission to expand access to our medically essential portfolio

In the first trial, investigators conducted a double-blind, randomized, parallel-group trial to assess whether or not silodosin – an investigational alpha blocker – would prolong the QT interval

Patients from Charm and Gain were followed through into a non-placebo controlled, ongoing open-label extension (OLE) trial. Patients enrolled from the blinded, randomized arms from Charm and Gain